AMRX | Amneal pharmaceuticals inc - Stock Value & PE Ratio Analysis

3

24

15

Limited Growth

AI analysis rates AMRX with a lower value score of 2.
It is mainly due to unstable operating cash flow, along with potential value may be lower.
Over the past 3 months, AMRX has maintained a consecutive value rating of 2.0, slightly lower than the rating of 3.3 over the past 3 years, indicating slight decrease in enterprise value.
Compared to all stocks in the Health Care sector, AMRX has a medium value rating.

AMRX Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/03 (Weekly Update)

AMRX Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

AMRX Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.16	-15.8%	23.1%	702.47M	17.3%	0.2%	0.9%
2024Q1	0.16	33.3%	14.3%	701.78M	25.9%	6.6%	-13.9%
2023Q3	0.14	-39.1%	100%	616.98M	1.2%	-7%	1.6%
2023Q2	0.19	58.3%	58.3%	620.04M	24.6%	-2.2%	2%
2023Q1	0.19	5.6%	90%	599.05M	11.6%	5.9%	-1.8%

Update to 2025/5/9 (Quarterly Update)

AMRX Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

AMRX Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of AMRX from 2007/01 till Now

10.66%
Cumulative Return: 0.58%
Annual Return: 56.56%
Volatility: 0.01
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 3)